Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study

Abstract

The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was licensed in Japan in 2009. HPV vaccine effectiveness against high‐grade cervical lesions has been demonstrated among young Japanese women, but evidence of its effects on invasive cervical cancer (ICC) is lacking. Using data from two different cancer registries, we compared recent trends of new ICC cases by age group using Poisson regression analysis. We also analyzed time trends in HPV16/18 prevalence among 1414 Japanese women aged <40 years newly diagnosed with ICC in the past decade. Based on the population‐based cancer registry, the incidence of ICC among young women aged 20–29 years showed a significant decline from 3.6 to 2.8 per 100 000 women‐years during 2016–2019, but no similar decline was observed for older age groups (p < 0.01). Similarly, using data from the gynecological cancer registry of the Japan Society of Obstetrics and Gynecology, the annual number of ICCs among women aged 20–29 years also decreased from 256 cases to 135 cases during 2011–2020 (p < 0.0001). Furthermore, a declining trend in HPV16/18 prevalence in ICC was observed only among women aged 20–29 years during 2017–2022 (90.5%–64.7%, p = 0.05; Cochran–Armitage trend test). This is the first report to suggest population‐level effects of HPV vaccination on ICC in Japan. Although the declining trend in HPV16/18 prevalence among young women with ICC supports a causal linkage between vaccination and results from cancer registries, further studies are warranted to confirm that our findings are attributable to vaccination.

The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers

“…Also, various biopsy techniques, including colposcopy [ 12 ], endometrial biopsy [ 13 ], hysteroscopy [ 14 ], and laparoscopy [ 15 ], are utilized to procure tissue samples from suspected tumors or abnormal regions for further analysis and confirmation. Molecular tests can identify specific biomarkers associated with GCs, such as human papillomavirus (HPV) testing for cervical cancer or genetic testing for ovarian cancer [ 16 , 17 ]. The treatment of GCs depends on various factors including the type and stage of cancer [ 18 ], overall health of the patient, and the patient’s preferences [ 19 ].…”